research Safety of dermatologic medications in pregnancy and lactation
Some skin medications are safe during pregnancy and breastfeeding, but others can harm the baby and should be avoided.
Search
for
Sort by
Research
30 / 1000+ results research Recurrence of Alopecia Areata in a Patient Receiving Etanercept Injections
Etanercept may not prevent alopecia areata from coming back.
research Safety of dermatologic medications in pregnancy and lactation
Most dermatologic medications are safe during pregnancy and breastfeeding, but some should be avoided due to potential risks.
research Drugs and Hair Loss
Some medications can cause hair loss, but stopping the drug usually leads to recovery within 3 months.
research Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database
Some drugs used to treat inflammation may cause hair loss.
research Successful etanercept therapy in therapy refractory acrodermatitis continua suppurativa Hallopeau
Etanercept effectively treated a severe skin condition when other treatments failed.
research Alopecia universalis during treatment with leflunomide and adalimumab - Case report
A patient lost all their hair while on rheumatoid arthritis medication.
research Concomitant occurrence of acneiform eruption, alopecia areata, and urticaria during adalimumab treatment in a patient with pustulosis palmoplantaris: Case report and literature review
A patient with PPP had rare skin reactions to adalimumab, which improved after stopping smoking and continuing acitretin.
research Innovative Therapeutics in Pediatric Dermatology
New treatments for skin conditions in children include a preferred drug for birthmark reduction, proactive creams for eczema and vitiligo, a safe psoriasis medication, and special tissues and socks for eczema and fungal infections.
research Alopecia areata in a patient with psoriatic arthritis and C rohn's disease receiving etanercept
Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.
research Psoriatic onychopachydermoperiostitis: improvement with etanercept
Etanercept improved symptoms of a specific type of psoriatic arthritis in a patient who didn't respond to other treatments.
research Cytokine-Targeting Biologic Therapies for Alopecia Areata: A Comprehensive Review of Mechanism of Action, Clinical Efficacy, and Adverse Events
Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.
research British Association of Dermatologists centenary year: standing on the shoulders of giants
The British Association of Dermatologists celebrated 100 years by looking back at important research, including work on hair loss, skin condition impact, psoriasis treatment, and skin cancer rates.
research Current systemic treatment strategies for hidradenitis suppurativa
Adalimumab is the most effective treatment for severe hidradenitis suppurativa, but more research is needed to improve treatment options.
research Psoriasis del cuero cabelludo etiología, diagnóstico y tratamiento
Scalp psoriasis is treated with topical therapies, phototherapy, and systemic medications.
research Data from Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
research Data from Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
research Biologic: A Double Edged Sword - A Case of Etanercept Induced Alopecia Areata in a Patient with Psoriasis Vulgaris
Etanercept, a psoriasis treatment, caused hair loss in a patient.
research Alopecia Universalis: an extremely rare but probable adverse effect of adalimumab
Adalimumab can cause complete hair loss in rare cases.
research PSS33 REAL-LIFE DOSING OF BIOLOGICS IN PLAQUE PSORIASIS—A GERMAN SURVEY
Real-life dosing of biologics for plaque psoriasis often deviates from recommended guidelines, especially for high-need patients.
research Adverse Effects and Drug Interactions of Biologic Agents
Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.
research Anticytokine therapy, particularly anti-IFN-γ, in Th1-mediated autoimmune diseases
Blocking interferon-gamma might help treat various autoimmune diseases.
research Successful rapid subcutaneous desensitization to anakinra in a case of delayed‐type hypersensitivity reaction
A woman with a drug allergy to anakinra was successfully desensitized, allowing her to continue treatment without allergic reactions.
research Endocrinologia e Medicina Estética Ed. X
A comprehensive, personalized approach is needed for treating female pattern hair loss and obesity, involving multiple medical disciplines and lifestyle changes.
research The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
research Finasteride for female androgenetic alopecia
Finasteride increases hair density in female androgenetic alopecia, but individual results may vary.
research A novel therapeutic paradigm for patients with extensive alopecia areata
New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
research Patient’s experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis
Methotrexate for rheumatoid arthritis often causes side effects like diarrhea, fatigue, and hair loss, especially at higher doses.
research New treatments for rheumatoid arthritis
New drugs for rheumatoid arthritis show improvement but have side effects and are not a cure.
research CUTANEOUS T-CELL LYMPHOMA
The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.